Henry Schein (HSIC) has been a topic of significant discussion. Recent analysis indicates
pressure on the company's shares till 2025. Despite downgrades and fluctuations,
Bank of America Securities and
Evercore maintain their
'buy' ratings on the stock. Henry Schein, however, is
underperforming the
Health Care sector, with some analysts suggesting alternatives to HSIC. The stock valuation is also influenced by weaker U.S Dental Demand, which could possibly shift HSIC's growth and valuation story. Despite such challenges, a
'Bull Case Theory' has been brought forward along with the company's solutions hub expansion and increase of US$750 Million
buyback scheme. Q2 Earnings, although in line with expectations, saw a fall in the share price due to an earnings miss.
Stock repurchases of $750 million were also announced, indicating a possible shift in capital allocation priorities. HSIC is consistently seen as a
value stock in the long term by analysts. Notwithstanding currency challenges, the company projects
strategic growth and strong performance in 2025.
Henry Schein HSIC News Analytics from Mon, 18 Nov 2024 08:00:00 GMT to Sat, 11 Oct 2025 15:34:34 GMT -
Rating 0
- Innovation 0
- Information 2
- Rumor 0
